Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Adalimumab biosimilar by Aprogen for Autoimmune Disorders: Likelihood of Approval
Adalimumab biosimilar is under clinical development by Aprogen and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase...
Data Insights
Adalimumab biosimilar by Biocon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to...